Amir Weiss - Mar 5, 2024 Form 4 Insider Report for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)

Role
Chief Accounting Officer
Signature
/s/ Dov Bergwerk as attorney-in-fact for Amir Weiss
Stock symbol
TEVA
Transactions as of
Mar 5, 2024
Transactions value $
$0
Form type
4
Date filed
3/7/2024, 04:08 PM
Previous filing
Mar 5, 2024
Next filing
May 17, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TEVA Ordinary Shares Options Exercise +3.56K +11.98% 33.3K Mar 5, 2024 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TEVA Restricted Share Units Options Exercise $0 -3.56K -49.99% $0.00 3.57K Mar 5, 2024 Ordinary Shares 3.56K Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
F2 Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
F3 Restricted share units were granted on March 5, 2021, with 3,564 vested on each of March 5, 2022 and March 5, 2023, 3,564 vesting on March 5, 2024, and 3,566 vesting on March 5, 2025.